Development of new active pharmaceutical ingredients (APIs) is lengthy and cost-intensive, thus avoiding any potential risk that may limit the product’s success is of utmost importance. Today, many APIs are not being commercialized because they are poorly water soluble and, as a result, exhibit too low bioavailability.
The Developability Classification System was developed to assist formulation scientists by introducing two new compound categories: dissolution rate limited (DCS IIa) and solubility limited (DCS IIb). Depending on where your API lies, there are various strategies to optimize formulation of poorly soluble molecules — From particle size reduction, to solid state modification, to API processing techniques like salt and cocrystal formation.
Speakers
Thomas Briel, Ph.D.
Merck
Strategic Marketing Manager, Excipients Liquid Application
Thomas Briel is strategic marketing manager at Merck and responsible for a broad portfolio of excipients for liquid formulation. He has more than 6 years of experience in the pharma and biopharma industry with different positions in the field of pharmaceutical formulation. Thomas holds a Ph.D. in biology from the Technical University of Munich. In parallel to his Ph.D. and industry roles, Thomas acquired a B.S. in economics with a focus on marketing.
Markus Lubda, Ph.D.
Merck
Strategic Business Manager
Markus is a biomolecular engineer. He is responsible for the strategic development and positioning of an excipient portfolio for oral solid dosage form applications. Thereby, the focus is to enhance solubility and bioavailability of the most challenging APIs with specifically engineered excipients for oral solid application. He holds a Ph.D. in biology/chemistry from the Technical University of Darmstadt and is a biomolecular engineer.
Pharma and biopharma manufacturing
- Liquid Formulation Strategies
Durée:1h 5min
Langue:English
Session 1:présenté(e) April 4, 2023
Pour continuer à lire, veuillez vous connecter à votre compte ou en créer un.
Vous n'avez pas de compte ?